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Several kinds of mushrooms are well-known in traditional medicine in Asia. Recent studies 
showed they have various pharmaceutical activities such as food and drug intoxication, anti-hypertension 
and anti-cancer. Among them, Basidiomycota and Ascomycota species attract much attention because of 
their specialized secondary metabolites and pharmaceutical activities, for example, anti-tumor drugs 
Lentinan from Lentinula edodes and Schizophyllan from Schizophylum commune.  
On the other hand, fungal infection happens often all over the world regardless species, gender 
or age. Nevertheless, antibiotic, salicylic acid and fatty acid type anti-fungal medicines were eliminated 
due to several reasons such as resistance, efficiency, side effects and the ability to making profits. And the 
tendency of anti-fungal drug elimination will accelerate in the future. Therefore, it is important to develop 
and discover new anti-fungal compounds/drugs before these problems become severe.  
In this study, my aim was tried to achieve anti-fungal compounds. By using Basidiomycota and 
Ascomycota cultured mycelia of mushrooms to isolate anti-microbial compounds for treating skin or oral 
infection. Moreover, I also tried to uncover the secondary metabolites produced by these cultured 
mycelia.  
 
Results  
 By means of paper-disk method, mycelium and culture broth from several kinds of 
Basidiomycota, and Ascomycota fungi were screened for the anti-microbial activity toward Microsporum 
canis, Candida albicans and Trichophyton rubrum. Among these fungi, Lignosus rhinoceros, Isaria sp. 
and Ganoderma mastporum showed strong bioactivities.  
1-1  Anti-fungal compounds from Lignosus rhinoceros 
 L. rhinoceros were cultured in liquid potato dextrose (PD) medium, at 25℃ in the dark. 
Culture broth (20L) of L. rhinoceros were condensed by evaporator to 2L, and then extracted with ethyl 
acetate (EtOAc) and then n-butanol (BuOH). The EtOAc and BuOH extracts were tested for the 
bioactivities toward M. canis, C. albicans and T. rubrum as bioactivity-guide. Through the 
bioactivity-guided fractionation procedure, the bioactive compounds 1 and 2 were isolated by silica-gel 
column chromatography and NP- HPLC. Compounds 1 and 2 (Figure 1) were found to have a peak by 
LR-EI-MS at m/z 166 and 200, respectively. Together with 1H-NMR, 13C-NMR and HMBC, compound 1 
was identified as 3,5-dimethoxybenzaldehyde, and compound 2 was identified as 2-chloro-3,5- 
dimethoxybenzaldehyde. This is the first report of anti-fungal compounds from L. rhinoceros. 
1-2  Secondary metabolites from L. rhinoceros 
Excepted the 2 bioactive compounds, 6 compounds (Figure 1) from the same fraction were 
isolated by silica-gel column chromatography and RP-HPLC named rel-(1S, 2R)-1-(3’,5’- 
dimethoxyphenyl)propane-1,2-diol (3), rel-(1R, 2R)-1-(3’,5’-dimethoxyphenyl)propane-1,2-diol (4), 
3,5-dimethoxybenzoic acid (5), 2-chloro-3,5- dimethoxybenzoic acid (6), 6-(2-hydroxypropyl)-4- 
methoxy-pyran-2-one (7) and 1-(2-chloro-3,5-dimethoxy-phenyl)-ethane-1,2-diol (8). 
 
Figure 1. Structure of compounds 1-8 
Compounds 2, 3, 4, and 7 are the first report from the natural product. Compound 8 is a new 
compound.  
 
2-1  Anti-fungal compounds from Isaria sp. 
 The culture broth of Isaria sp. showed strong bioactivity toward both M. canis and C. albicans. 
As the result, large scale culture was carried out for compounds isolation. However, the bioactive fraction 
was seemed to exist as a compound which contains several conformations and is difficult to analyze by 
NMR. Several methods were tried in order to understand the structure including isolation properties, 
methylation and acid treating. Unfortunately, larger amount of the sample is necessary for the further 
application. 
2-2  Secondary metabolites from Isaria sp. 
 The mycelia of cultured Isaria sp. was freeze dried and then extracted with methanol for 
studying of its secondary metabolites. The extract was applied to silica-gel column chromatography, 
NP/RP-HPLC to give compounds 9, 10, 11, 12 and 13 (Figure 2). According to NMR and MS spectra, 
compound 9, 10, 11 and 12 are 3β,5α-dihydroxyergosta-7,22-dien-6-one, 5α,6α-epoxyergosta-7,22- 
dien-3β-ol, 3β,5α,9α-trihydroxyergosta- 7,22-dien-6-one and 6α,9α-epoxyergosta-7,22-dien-3β-ol, 
respectively. And compound 13 was identified as a new compound which was found to have a peak by 
HR-ESI-MS of m/z 467.3047 [M+Na]+ with a molecular formula C28H44O4.  
 
Figure 2. Structure of compounds 9-13 
 
3  Anti-microbial compounds from Ganoderma mastporum 
 According to paper disk method results of M. canis, 
mycelia extract of G. mastporum showed bioactivity. By means 
of bioactive guide fractionation method, the extract was applied 
to silica-gel column chromatography, NP/RP-HPLC to obtain 
compounds 14, 15, 16, 17 and 18 (Figure 3). They are benzoic 
acid, meso-hydrobenzoin, ergosterol, ergosterol-peroxide and 
ergostatrien-3β-ol, respectively. The anti-fungal results showed 
compounds 14 and 17 have anti-fungal activity.  
 
Conclusion 
 By means of bioactivity-guided fractionation procedure, bioactive compounds 1 and 2 were 
isolated from L. rhinoceros, and compounds 14 and 17 were isolated from G. mastoporum. As to 
secondary metabolites discovery, 2 new compounds were isolated from this study. Nowadays, resistance 
to antibiotics in pathogenic fungi is a problem. And limited number of antifungal drugs makes this 
phenotype and acute problem. Investigation in this study will can give a help to solve this problem. 
